Pamrevlumab Trials
Pamrevlumab Trials
Pamrevlumab, our proprietary fully human antibody, targets connective tissue growth factor (CTGF), a common factor in proliferative disorders as well as certain cancer cell types. Pamrevlumab is in Phase 3 clinical studies for the treatment of metastatic pancreatic cancer, locally advanced pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD).
Pancreatic Cancer
Precision PromiseSM Platform Study, Phase 2/3, Randomized, Open-label, A Multi-Center Trial Evaluating Multiple Regimens in Patients with Stage IV Metastatic Pancreatic Cancer
For more information on this study, please visit
LAPIS Study – FG-3019-087, Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination with Gemcitabine Plus Nab-paclitaxel (G/NP) as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer
For more information on the study, please contact